✦ LIBER ✦

Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions

✍ Scribed by Teixeira, Rosângela; Nascimento, Yone de Almeida; Crespo, Déborah

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Drug interactions and protease inhibitor

✍ S. Talavera Pons; G. Lamblin; A. Boyer; V. Sautou; A. Abergel 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 313 KB

Cutaneous adverse drug reaction to pegyl

✍ Kinaciyan, T.; Jessner, W.; Formann, E.; Hayek, B.; Steindl-Munda, P.; Ferenci, 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 132 KB

1201 IN VITRO ASSESSMENT OF POTENTIAL DR

✍ Park, S.H.; Ward, W.; Beaudet, B.; Schock, S.; Randolph, R.; Wring, S. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 67 KB

Efficacy and safety of telaprevir, a new

✍ N. Hayashi; T. Okanoue; H. Tsubouchi; J. Toyota; K. Chayama; H. Kumada 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 231 KB

Clinical Assessment of Potential Drug In

✍ Sabo, J. P.; Kort, J.; Ballow, C.; Haschke, M.; Battegay, M.; Fuhr, R.; Girlich, 📂 Article 📅 2014 🏛 University of Chicago Press 🌐 English ⚖ 509 KB

An evaluation of risk factors for advers

✍ Takeshi Morimoto; Tejal K. Gandhi; Julie M. Fiskio; Andrew C. Seger; Joseph W. S 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB